Kite Pharma
1601 Cloverfield Blvd., 100 South Tower
Santa Monica
CA
90404
United States
Tel: 424301-3670
28 articles about Kite Pharma
-
The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions.
-
Gilead’s Kite Teams Up with Sangamo Therapeutics for Cancer Therapeutics in a $3.1 Billion+ Deal
2/22/2018
Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics. -
The latest acquisition makes it the highest amount paid for a flex R&D building in Los Angeles County.
-
ASH Burns Bright With Excitement
12/12/2017
A look at some of the exciting data clinicians and investors got to feast on from ASH. -
The ZUMA-3 study results were presented in an oral session at the Annual Meeting of the ASH in Atlanta.
-
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma
12/11/2017
With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission.
-
CAR-T is a hot new area and there are companies hot on Gilead's tail, namely Juno, in a partnership with Celgene, and Novartis.
-
BioLife Solutions Customer Kite Pharma Receives FDA Approval for Yescarta™ (Axicabtagene Ciloleucel) CAR T-Cell Therapy
10/19/2017
BioLife Solutions today announced that its customer Kite Pharma has received US FDA approval for Yescarta, the first CAR T-cell therapy for treatment of adult patients with relapsed or refractory large B-Cell lymphoma after two or more lines of systemic therapy.